New research suggests that the origins of devastating neurodegenerative diseases might not lie solely within the brain, but rather in the gut. A study led by researchers at Case Western Reserve University has identified a potential link between specific bacterial sugars and the onset of Amyotrophic Lateral sclerosis (ALS) and frontotemporal dementia (FTD).
The Connection Between Gut and Brain
ALS and FTD are closely related conditions characterized by the progressive death of neurons. While ALS primarily targets motor neurons—leading to the loss of muscle control—FTD impacts behavior, personality, and language.
For years, scientists have struggled to understand why some people develop these diseases while others do not, even when they carry the same genetic predispositions. This study focuses on the C9ORF72 gene variant, a common genetic factor in both diseases. However, because not everyone with this mutation falls ill, researchers have been searching for “environmental triggers”—external factors that might push a genetically predisposed person toward actual disease onset.
The Discovery: Inflammatory Sugars
By using mouse models engineered to mimic the human C9ORF72 mutation, the research team discovered that certain gut bacteria produce a specific type of sugar called glycogen.
The study identified a specific bacterium, Parabacteroides merdae, as a primary culprit. When this bacteria was introduced to mice, it triggered a chain reaction:
1. Glycogen Production: The bacteria produced inflammatory forms of glycogen.
2. Immune Overdrive: The body detected these sugars as threats, causing the immune system to overreact.
3. Brain Inflammation: This immune response led to severe inflammation and a breakdown of the blood-brain barrier, allowing damage to reach the brain and kill neurons.
Evidence in Humans
The findings were not limited to animal models. When researchers analyzed human stool samples, they found a significant correlation:
– ALS patients: 15 out of 22 showed abnormally high levels of inflammatory glycogen.
– Healthy controls: Only 4 out of 12 showed these elevated levels.
This suggests that the C9ORF72 protein normally acts as a “brake” on glycogen production. When the gene is mutated, that brake fails, allowing bacterial sugars to run unchecked and trigger neurodegeneration.
A New Path for Treatment
One of the most promising aspects of this research is the potential for gut-targeted therapies. In mouse trials, researchers administered alpha-amylase —an enzyme that breaks down glycogen. The results were significant:
– Reduced inflammation levels in the brain.
– Extended lifespans for the affected mice.
Interestingly, while the enzyme helped the mice live longer, it did not improve their physical motor performance, indicating that while the treatment can slow the disease’s progression, it may not yet be able to reverse existing damage.
“Our demonstration that microbes that accumulate inflammatory forms of glycogen are enriched in the gut of ALS patients suggests that microbial glycogen may be an important example among many environmental and lifestyle factors that interact with predisposing genotypes,” the researchers noted.
Looking Ahead
This research shifts the focus of neurodegenerative treatment from the brain to the digestive system. The next steps for the team include:
– Conducting larger studies to monitor gut microbiome changes in humans before and after disease onset.
– Launching clinical trials—potentially within a year—to see if glycogen-degrading treatments can slow disease progression in human patients.
Conclusion: By identifying bacterial glycogen as a potential driver of brain inflammation, this study opens a new frontier in neurology, suggesting that managing gut health could be a key strategy in slowing or preventing the progression of ALS and FTD.
